CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 136 enrolled
Drug / intervention
GSK1838262 Extended Release Tablets +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00748098
NCT00748098Phase 3Completed
CompareCT.gov

Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance

XenoPort, Inc.·interventional·Posted Sep 8, 2008·Updated Jul 22, 2013

In Brief

A Phase 3 clinical trial evaluating GSK1838262 Extended Release Tablets and Placebo for Restless Legs Syndrome and Restless Legs Syndrome (RLS). Completed, enrolled 136 participants across 24 sites.

Detailed Summary

The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRestless Legs Syndrome, Restless Legs Syndrome (RLS)
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 8, 2008
Enrollment StartOct 1, 2008
Primary CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.8 years ago

Interventions

GSK1838262 Extended Release Tabletsdrug

GSK1838262 extended release tablets

Placebodrug

Placebo